An adaptive randomised placebo controlled phase II trial of antivirals for COVID-19 infection (VIRCO): A structured summary of a study protocol for a randomised controlled trial
Letter
[키워드] 1:1
7-point ordinal scale
adaptive
Alfred Hospital
allergy
Antiviral
Antiviral treatment
Arm
biomarkers of inflammation
blinded to treatment
childbearing potential
clinical
clinical benefit
clinical symptom
clinical trial
Community
Confirmed
Contraception
COVID-19
COVID-19 infection
Day
defined
determine
dialysis
dissemination
dose
effective
Efficacy
element
eligible
enrolled
enrolment
Favipiravir
female
fertile
GRADE
hospitalisation
hospitalised
immune activation
ineligible
investigator
male
medication
negative pregnancy test
nucleic acid
number
objective
outcome
parallel-group
participant
Participants
Patient
performed
Pharmacy
Placebo
protocol
randomisation
randomised
randomised controlled trial
recruit
recruited
recruitment
renal impairment
Sample size
SARS-CoV-2
Screening
secondary
severe hepatic dysfunction
Standard of care
status
stratified
Study protocol
study visit
Swab
Symptom
the WHO
time
Treatment
Trial
triple-blind
Victoria
virological cure
website
[DOI] 10.1186/s13063-020-04766-5 PMC 바로가기 [Article Type] Letter
[DOI] 10.1186/s13063-020-04766-5 PMC 바로가기 [Article Type] Letter